The antiepileptic drug topiramate increases the risk of cleft lip and cleft palate in babies whose mothers take the medication during pregnancy, new data reported by the United States Food and Drug Administration (FDA) suggest. Topiramate is approved to treat certain types of epileptic seizures and to prevent, but not relieve the pain of, migraine headaches.
The antiepileptic drug topiramate increases the risk of cleft lip and cleft palate in babies whose mothers take the medication during pregnancy, new data reported by the United States Food and Drug Administration (FDA) suggest. Topiramate is approved to treat certain types of epileptic seizures and to prevent, but not relieve the pain of, migraine headaches.
Data from the North American Antiepileptic Drug (AED) Pregnancy Registry, which collects information about outcomes in infants born to women treated with antiepileptic drugs, show that infants exposed to topiramate single therapy during the first trimester of pregnancy had a 1.4% prevalence of oral clefts, whereas infants exposed to other antiepileptics had a prevalence of 0.38% to 0.55%. Babies whose mothers did not have epilepsy and who weren’t being treated with other antiepileptic drugs had a prevalence of 0.07%.
“Healthcare professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age," said Russell Katz, MD, director of the Division of Neurology Products, FDA Center for Drug Evaluation and Research. “Alternative medications that have a lower risk of birth defects should be considered.”
Based on the new data, FDA will update the patient medication guide and prescribing information for topiramate and change the drug’s pregnancy category from C to D (ie, positive evidence of human fetal risk based on human data, but potential benefits may outweigh the risks in certain situations).
Pregnant women who are taking topiramate should talk to their physician about registering with the North American AED Pregnancy Registry: http://www2.massgeneral.org/aed/.
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Integrating pharmacists into PPHTN management for enhanced blood pressure control
December 4th 2023A study reveals that involving pharmacists in the care of postpartum women at risk of persistently elevated blood pressure, as presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition, can provide an effective and feasible solution to managing hypertensive disorders, reducing postpartum readmission risks, and improving overall health care access.
Read More